The SkelRegen Management Team is a carefully selected group of three accomplished individuals with proven track records and synergy in the discovery, translation and commercial growth of the most successful bone biologic products currently available.
Stephen R. La Neve, MBA
Steve La Neve, Co-Founder and CEO of SkelRegen, LLC brings thirty years of health care experience, leadership and success to the position. He has held leadership roles in the device and diagnostic segments, most recently as president of Becton Dickinson’s Pre-Analytical Systems business, president of Medtronic’s $3.5b Spine and Biologics business and president of Medtronic’s second largest country business unit, Medtronic Japan. Steve, also served as senior vice president and executive vice president at Premier, one of the largest GPOs in the United States, and ran the global Injection Systems business unit for Becton Dickinson. Additionally, Steve has served in a number of commercial leadership roles at Becton Dickinson, Roche Diagnostics and E Merck Diagnostic Systems to include, sales, marketing, strategic planning and project management both in the US and outside the US. Steve consults for private equity companies in the medical device area. Steve has a B.S. in Health Planning and Administration from the Pennsylvania State University, an MBA from West Chester University, and is a member of the omicron delta epsilon honor society for academic excellence in economics.
Scott D. Boden, MD
Dr. Scott Boden is Co-Founder and Chief Medical and Technology Officer of SkelRegen, LLC. He is also a tenured Professor of Orthopaedic Surgery at the Emory University School of Medicine and serves as the Director of the Emory Orthopaedics & Spine Center, Vice Chair of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs. He is also the Clinical Director of the Whitesides Orthopaedic Research Laboratory and has received many awards, authored over 175 peer-reviewed articles on spine and basic science topics, as well as 30 chapters and 7 textbooks. He is Co-Editor of Seminars in Spine Surgery, a Deputy Editor of SPINE, and a reviewer for The Journal of Bone and Joint Surgery, The Journal of Bone and Mineral Research, and the European Spine Journal. Dr. Boden served as Secretary of the American Orthopaedic Association and will serve as AOA President in 2013-2014. Dr. Boden received his B.A. and M.D. from the University of Pennsylvania and completed an Orthopaedic Residency at The George Washington University Medical Center, followed by a Spine Fellowship at Case Western Reserve University Hospitals.
John M. Wozney, PhD
John Wozney is Director of Scientific Affairs and Co-Owner at SkelRegen, LLC, with more than 25 years’ experience in the pharmaceutical industry and scientific leadership. After joining the biotechnology company Genetics Institute (acquired by Wyeth and subsequently Pfizer), he conducted research leading to the identification of Bone Morphogenetic Proteins, which are key-signaling molecules involved in the growth and maintenance of bone and soft tissues. He then played a key role in the commercialization of a genetically engineered human BMP-2 recombinant protein and the development of a local delivery system as an innovative bone-inductive therapeutic which has found widespread use in orthopaedics. Dr. Wozney is an internationally recognized expert in the fields of BMP and musculoskeletal biology. While at Genetics Institute/Wyeth/Pfizer, he assumed positions of increasing responsibility for the BMP-related research and development activities, and served as Assistant Vice President. He is the author of more than 150 peer-reviewed publications and an inventor on more than 50 issued U.S. patents. He received both his A.B. and Ph.D. degrees in biochemistry from Harvard University and subsequently was a post-doctoral fellow at Massachusetts Institute of Technology.